ERBB2 and neoplasm: Taking into account the potential limited duration of response and our findings of low immune cell infiltration in HER2 positive EAC, it remains unclear if the response triggered by anti-tumor immunity in HER2 positive gastroesophageal adenocarcinoma will result in clinically relevant survival benefit.